What is pathophysiology of Urticaria?

['Nan jaawal ndu']

Ko woni patofisioloji ɓuutol?

Urticaria, je ɓe ɓuri anndugo bana ɓuutol, lati bana nyau ɓandu je ɗon holla wurtaaki ɓuutolji je ɗon wullu, je ɗon ummina, je ɗon mari ɓalewol do ɓandu.

Pathophysiology urticaria ɗon larna wurtinol histamine be kujeji je ɗon hokka ɓaandu fuɗɗam diga mast cellji, je lati ɓikkoy fadol ɓaandu je ɗon tawama ha nder laral be kujeji feere.

Ha nder ɓernde je ɗon mari ɓernde je ɗon mari nyau, wurtinol histamine be kujeji feere ɗon waɗa ngam no goɗɗo ɗon mari nyau be kujeji feere, bana nyamdu, lekki, mala to goɗɗo ɗon mari nyau be gilɗi.

Ndu ɗon hokka mast cellji wurtina histamine be kujeji feere je ɗon hokka iyam ɓilla, je ɗon hokka wurtol gilɗi.

Ha nder ɓernde je ɗon tokkita, ɗon aandi ko ɗon hokka ndu, amma ɗon tammi ndu ɗon yahida be dabare ɓaandu je ɗon nyaɗina ndu.

Ha wakati ndu, ɓaandu ɗon wurtina fadooɓe ɓaandu je ɗon nyaama jaɓɓowo IgE je ɗon mari sembe (FcεRI) ha do mast cellji, je ɗon yahda be huwugo maɓɓe e wurtinugo histamine be dabareji feere.

Ha nder ɓernde je ɗon mari nyaɗugo be je ɗon mari nyaɗugo, wurtinol histamine be kujeji feere ɗon hokka mandolji bana wulugo, ɓalewol, be wulol.

Hurgol ɗon larna huwugo be lekki antihistamines ngam darnugo kuɗe histamine e ustugo mandolji nyau.

Ha nder nyauɓe je nyaɗay, lekkiji feere bana corticosteroids mala omalizumab footi naffa ngam aynugo nyau man.

['Ɗaɓɓitol']

PubMed/Medline https://www.nlm.nih.gov/databases/download/pubmed_medline.html

RefinedWeb https://arxiv.org/abs/2306.01116

Wahlgren CF: Pathophysiology of itching in urticaria and atopic dermatitis. Allergy. 1992, 47 (2 Pt 1): 65-75.

Raap U, Liekenbröcker T, Wieczorek D, Kapp A, Wedi B: [New therapeutic strategies for the different subtypes of urticaria]. Hautarzt. 2004, 55 (4): 361-6.

[Recommendations for the diagnosis and treatment of urticaria in children]. Arch Argent Pediatr. 2021, 119 (2): S54-S66.

Marrouche N, Grattan C: Childhood urticaria. Curr Opin Allergy Clin Immunol. 2012, 12 (5): 485-90.

Brzoza Z, Grzeszczak W, Rogala B, Trautsolt W, Moczulski D: Possible contribution of chemokine receptor CCR2 and CCR5 polymorphisms in the pathogenesis of chronic spontaneous autoreactive urticaria. Allergol Immunopathol (Madr). , 42 (4): 302-6.

Sweeney TM, Dexter WW: Cholinergic urticaria in a jogger: ruling out exercise-induced anaphylaxis. Phys Sportsmed. 2003, 31 (6): 32-6.

['Wurtinol: jam ɓaandu']

['Web site ndu ɗon hokka ngam ekkitol be matinolji tan e wala bana hokkugo feeloji do jam ɓaandu mala kuɗe.']

["Matinolji je ɗon hokka footay huwire ngam lartol mala hurgol nyau mala nyauji, e ɓe'en je ɗon ɗaɓɓita feelo lekki sey ɓe laara do lekkitajo je mari jaawal."]

['Ladde ngam matinolji je ɗon wurtina jaawabuji do emmolji, lati bana je ɗon mari limgal je ɗon larni nyauɓe.']

['Footi a ɗaɓɓita jaahargal do lekkitajo ma mala goɗɗo dokkoowo jam ɓaandu je mari daama do nyau ma. Taa meema jaahargal do lekkitajo mala neeɓu ɗaɓɓugo ndu ngam ko a jaangi ha do wakkere web ndu. To a tammi a footi mara nyau jaawal, ewna 911 mala yah ha suudu jaawal je ɓadi ma be law. Wala alaka lekkitajo be nyauɗo je ɗon wangina gal wakkere web ndu mala huwugo ndu. BioMedLib mala huwooɓe ma, mala goɗɗo je ɗon walli ha wakkere web ndu, ɗon wolwa, ɗon holla mala ɗon nufa, do matinolji je ɗon hokka ha nder ndu mala huwugo ndu.']

['Wurtinol hakke: copyright']

["Digital Millennium Copyright Act je 1998, 17 U.S.C. § 512 (DMCA) ɗon hokka dabare ngam marɓe hakkeji je ɗon hoola yo'o kujeji je ɗon wangi ha do Internet ɗon luuta hakkeji maɓɓe do dooka hakkeji je Lesɗe America. "]

["To a ɗon nuɗɗini be nuɗɗinki boɗɗum yo'o kujeji mala kujeji je ɗon no wondi be web site mala kuɗe amin ɗon meema ceede je mari, an (mala wakili'en ma) footi nelda amin matinol je ɗon emma ngam ittugo kujeji mala kujeji, mala haɗugo heɓugo ndu. "]

['Matinolji sey nelda be ɗerewol gal emayel (laaru "Contact" ngam emayel).']

["DMCA yiɗi matinolji je ɗon bana ɗon larni matinolji je ɗon tokkitini: (1) tindol kugal je mari hakkeji je ɗon larni je ɗon tokkitini; (2) tindol kuje je ɗon larni je ɗon larni e matinolji je ɗon mari hakkeji je ɗon mari haaje ngam en heɓta kuje man; (3) matinolji ngam a wonda be ma, be lamar, lamba telefon be lamar email; (4) matinol je a holli a ɗon hoola be goonga yo'o kuje je ɗon no ɗon holla bana ɗon larni wala jaɓol marɗo hakkeji, mala wakiilijo maako, mala gal kugal dookaaji; "]

['(5) matinolji je on windi, je on windi ha les bone seedugo fewre, je matinolji ha nder matinolji man lati goonga e je on mari baawɗe ngam aynugo hakkeji je mbiyotto ɗon luuta;']

['e (6) jungo je ɗon mari hakkeji mala jungo je ɗon mari bawɗe huwugo ngam inde je mari hakkeji. ']

['Wattinugo matinolji je woni ha ton footi waɗa jaawal ngam jaɓɓugo do ngulli maɗa.']

['Wondugo']

['Lorte ha amin be emel to a mari ƴamol/dabare.']

What is pathophysiology of urticaria?

Urticaria, commonly known as hives, is a skin condition characterized by the appearance of itchy, raised, red welts (wheals) on the skin.

The pathophysiology of urticaria involves the release of histamine and other inflammatory mediators from mast cells, which are immune cells found in the skin and other tissues.

In acute urticaria, the release of histamine and other mediators is triggered by an allergic reaction to a specific allergen, such as food, medication, or insect sting.

This causes the mast cells to degranulate, releasing histamine and other mediators that cause blood vessels to become leaky, leading to the formation of wheals.

In chronic urticaria, the cause is often unknown, but it is thought to be related to an autoimmune mechanism.

In this case, the body produces autoantibodies that target the high-affinity IgE receptor (FcεRI) on mast cells, leading to their activation and the release of histamine and other mediators.

In both acute and chronic urticaria, the release of histamine and other mediators leads to the characteristic symptoms of itching, redness, and swelling.

Treatment typically involves the use of antihistamines to block the effects of histamine and reduce symptoms.

In severe cases, other medications such as corticosteroids or omalizumab may be used to control the condition.

Disclaimer: medical

This web site is provided for educational and informational purposes only and does not constitute providing medical advice or professional services.

The information provided should not be used for diagnosing or treating a health problem or disease, and those seeking personal medical advice should consult with a licensed physician.

Please note the neural net that generates answers to the questions, is specially inaccurate when it comes to numeric content. For example, the number of people diagnosed with a specific disease.

Always seek the advice of your doctor or other qualified health provider regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. If you think you may have a medical emergency, call 911 or go to the nearest emergency room immediately. No physician-patient relationship is created by this web site or its use. Neither BioMedLib nor its employees, nor any contributor to this web site, makes any representations, express or implied, with respect to the information provided herein or to its use.

Disclaimer: copyright

The Digital Millennium Copyright Act of 1998, 17 U.S.C. § 512 (the “DMCA”) provides recourse for copyright owners who believe that material appearing on the Internet infringes their rights under U.S. copyright law. If you believe in good faith that any content or material made available in connection with our website or services infringes your copyright, you (or your agent) may send us a notice requesting that the content or material be removed, or access to it blocked. Notices must be sent in writing by email (see 'Contact' section for email address) . The DMCA requires that your notice of alleged copyright infringement include the following information: (1) description of the copyrighted work that is the subject of claimed infringement; (2) description of the alleged infringing content and information sufficient to permit us to locate the content; (3) contact information for you, including your address, telephone number and email address; (4) a statement by you that you have a good faith belief that the content in the manner complained of is not authorized by the copyright owner, or its agent, or by the operation of any law; (5) a statement by you, signed under penalty of perjury, that the information in the notification is accurate and that you have the authority to enforce the copyrights that are claimed to be infringed; and (6) a physical or electronic signature of the copyright owner or a person authorized to act on the copyright owner’s behalf. Failure to include all of the above information may result in the delay of the processing of your complaint.